Stockscreener 앱 받기
240.91
6.18%
14.02
Moderna Inc 주식(MRNA)의 최신 뉴스
Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy? - The Motley Fool
Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors. - The Motley Fool
Sandisk Is Dominating the S&P 500 in 2026. Can It Repeat in 2027? - The Motley Fool
Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline - The Motley Fool
The Nasdaq-100's 6 Best Stocks This Year, and Whether They Can Keep Going - The Motley Fool
Form 4 Moderna Inc: Stephen Hoge (President) For: 14 October By Investing.com - Investing.com Nigeria
Meet the New Nasdaq-100 Stock That’s Crushing Nvidia, Micron, and Sandisk. Is It Too Late to Buy? - The Motley Fool
Moderna Executive Stephen Hoge Announces Intent to Sell 39,145 Shares Under Rule 144 - Kalkine Media
MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell? - Zacks Investment Research
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Here's Why Moderna (MRNA) Fell More Than Broader Market - Zacks Investment Research
Tempus AI Expands Strategic Collaborations to Drive Future Growth - Zacks Investment Research
Lori Trahan Stock Trades and Disclosures - TechGraph
Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell? - The Motley Fool
Daniel S Sullivan Stock Trades and Disclosures - TechGraph
Moderna surges 12.6% after hours, adding roughly $11 billion in value - 24/7 Wall St.
Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock? - Zacks Investment Research
Is Invesco S&P 500 Equal Weight ETF (RSP) a Strong ETF Right Now? - Zacks Investment Research
Form 4 Moderna Inc For: 7 October By Investing.com - Investing.com Canada
Form 4 Moderna Inc For: 7 October By Investing.com - Investing.com UK
Moderna (MRNA) CFO has 704 shares withheld for taxes after converting a stock grant. - Stock Titan
Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity? - Zacks Investment Research
Moderna (MRNA) COO Juan Andres reports direct ownership of 125,000 common shares. - stocktitan.net
Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Moderna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026 - GlobeNewswire Inc.
Moderna (MRNA) Stock Dips While Market Gains: Key Facts - Zacks Investment Research
Moderna Inc (MRNA) Stock News & Articles - 24/7 Wall St.
Prediction: Moderna Stock Will Soar 100% by 2030 - The Motley Fool
Stock Market Midday, Sept. 30: Markets Rise on Softer Inflation Data, Investors Await Micron Earnings - The Motley Fool
Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now? - Zacks Investment Research
Up Over 550% in 2026, Is It Too Late to Buy Moderna Stock? - The Motley Fool
Moderna stock at USD 198.88 on September 25, 2026, up 2.08 percent - AD HOC NEWS
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate - Zacks Investment Research
3 Bullish Setups for the Week Ahead - Zacks Investment Research
Moderna, Inc.Common Stock (NQ: MRNA - The Chronicle-Journal
Moderna, Inc.Common Stock (NQ: MRNA - The Chronicle-Journal
Moderna (MRNA) insider exercises options, sells 80K shares - stocktitan.net
Moderna, Inc.Common Stock (NQ: MRNA - The Chronicle-Journal
Another multimillion stock sale lined up for 2026 at Moderna (NASDAQ: MRNA) - stocktitan.net
Moderna (MRNA) CFO sells 34,836 shares under pre-set plan - stocktitan.net
Insider at Moderna (NASDAQ: MRNA) plans multimillion-dollar stock sale for 2026 - stocktitan.net
Top Biotech Stocks To Watch TodaySeptember 13th - MarketBeat
Promising Biotech Stocks To Keep An Eye OnSeptember 12th - MarketBeat
California State Teachers Retirement System Buys 27,274,128 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know - Yahoo Finance
Moderna stock gains after a 6.7 percent jump - ad-hoc-news.de
Healthcare Stocks To Keep An Eye OnSeptember 11th - MarketBeat
Moderna Inc Stock (MRNA) Moved Up by 8.63% on Sep 11: A Full Analysis - TradingKey
MRNA Looks 517.6% Overvalued on GF Value™ as Price-to-Sales Soars Amid Losses - GuruFocus
MRNA Stock Climbs As Analysts Back Oncology And Vaccine Push - StocksToTrade
2.05%
1.25%
자본화:
|
볼륨(24시간):